Specifically, we used immunostaining to assess the density of positive glioma cells for two proliferation markers, Ki67 and 5-bromo-2′-deoxyuridine (BrdU, administered i.p. 24 h before sacrifice). The gene discussed is MKI67; the disease is central nervous system cancer.